Harbour BioMed receives China NMPA approval for Batoclimab injection (subcutaneous injection) for the treatment of generalized myasthenia gravis

Summary

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass. , ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 — Harbour BioMed (the "C...